New therapeutic strategies to treat ALS

Ana Martinez

Project awarded in collaboration with the Fundación Luzón

  • PROJECT LEADER

    Ana Martinez

  • HOST ORGANIZATION,
    COUNTRY

    Centro de Investigaciones Biológicas Margarita Salas, CSIC, Spain

  • DESCRIPTION

    The pathological accumulation of TDP-43 protein is associated with the appearance of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), a fatal disease urgently in need of effective treatments.

    The development of drugs that enable recovery of the TDP-43 protein function in the motor neurons of people with ALS is a novel therapeutic approach.

    The project focuses on investigating certain kinase inhibitors that may ultimately lead to promising personalised therapies to treat ALS and other pathologies by regulating the physiological balance of TDP-43.

  • PARTNER ORGANIZATIONS

    • Faculdade de Farmácia da Universidade de Lisboa, Portugal

    • Facultad de Medicina, Universidad Complutense de Madrid, Spain

    • IMDEA Nanociencias, Spain

  • PROJECT TITLE

    Targeting TDP-43 with protein kinase inhibitors: a effective and measurable therapy for ALS

  • BUDGET

    €500,000